Drug intelligence / Profile preview

VXN-SPOR

Development stage: Preclinical
Lead developer: Vaxinano
Modality: Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics

Overview

VXN-SPOR is a nanoparticle-based vaccine candidate developed by Vaxinano for the prevention of sporotrichosis in cats. It is built upon the proprietary STELLAR-NP platform, which utilizes inactivated pathogens to induce a robust immune response without the need for conventional chemical adjuvants. The vaccine targets *Sporothrix* species, the causative agents of sporotrichosis, a fungal disease that is particularly prevalent in feline populations and poses a zoonotic risk to humans. By delivering inactivated fungal components via a nanoparticle delivery system, VXN-SPOR aims to provide a safe and effective prophylactic solution. The candidate is currently in mid-stage development for veterinary use.

Other names: Vaxinano Sporotrichosis vaccineVXN-SPOR nanoparticle vaccine

Beyond the preview

Go deeper on VXN-SPOR.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VXN-SPOR.

Explore the full profile